Moderna, Merck's skin cancer vaccine shows sustained benefit after five years

Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in combination with Keytruda, reduced the risk of recurrence or death by 49% in a mid-stage trial. ...